Process Intensification: Distinguish Fact from Fiction

Misconception 1: Scaling Up Automatically Increases Efficiency
While expanding process scale is expected to boost output, in practice limitations in mass transfer and heat management can reduce efficiency. This misconception stems from experience with traditional batch processes. Scale‑up does not inherently equate to process optimization and signals a need for redesign across the industry.
Misconception 2: Existing Equipment Can Be Used As‑Is
The idea of applying new process‑intensification technologies to existing equipment originates from a desire to lower upfront capital costs. However, advanced technologies such as microfluidics require design changes and may introduce compatibility issues. Consequently, companies must consider full equipment retrofits or new installations.
Misconception 3: Cost Savings Are Immediate
Claims that process intensification lowers costs may hold only partially during early stages. Expenses for equipment replacement, workforce retraining, and validation are part of the initial investment, making short‑term cost reductions difficult. Over the long term, improved manufacturing efficiency and product quality drive cost recovery.
Misconception 4: Regulatory Approval Is Not a Major Issue
Intensified processes introduce new process parameters and quality‑control criteria, making communication with regulatory agencies critical. Regulatory concerns arise because risk‑management elements differ from those of previously approved processes. Without a proactive regulatory strategy, launch timelines may be delayed.
Process intensification enhances productivity and reduces costs, thereby improving long‑term profitability and strengthening investment appeal. As a result, demand for R&D personnel and regulatory‑affairs experts is increasing.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/spons/process-intensification-separating-fact-from-fiction/820433/